# Surgery Partners, Inc. (SGRY)

Informational only - not investment advice.

CIK: 0001638833
SIC: 8062 Services-General Medical & Surgical Hospitals, NEC
SIC breadcrumb: [Services](/division/I/) > [SIC Major Group 80](/major-group/80/) > [SIC 8062 Services-General Medical & Surgical Hospitals, NEC](/industry/8062/)
Latest 10-K filed: 2026-03-02
SEC page: https://www.sec.gov/edgar/browse/?CIK=1638833
Filing source: https://www.sec.gov/Archives/edgar/data/1638833/000163883326000008/sgry-20251231.htm

## At a glance

FY2025 · period end 2025-12-31 · filed 2026-03-02 · accession 0001638833-26-000008 · source: https://data.sec.gov/api/xbrl/companyfacts/CIK0001638833.json

| Metric | Value | FY | Provenance |
| --- | ---: | ---: | --- |
| Revenue | 3,308,700,000 USD | 2025 | verified |
| Net income | -77,900,000 USD | 2025 | verified |
| Assets | 8,119,700,000 USD | 2025 | verified |
| Free cash flow | 195,600,000 USD | 2025 | computed |
| Net margin | -2.35% | 2025 | computed |
| Operating margin | 11.77% | 2025 | computed |
| Revenue YoY | +6.24% | 2025 | computed |
| ROE | -4.55% | 2025 | computed |

Computed values are grepcent-computed from the verified facts above and may differ from ratios the company itself reports. Free cash flow = operating cash flow − capital expenditures. Net margin = net income ÷ revenue. Operating margin = operating income ÷ revenue. Revenue YoY = FY2025 revenue ÷ FY2024 revenue − 1 (consecutive fiscal years only). ROE = net income ÷ period-end stockholders' equity.

No market price, no rating, no forecast on this site. Not investment advice.

### Peer percentile fingerprint

| Ratio | SGRY | Peer median | Percentile | N |
| --- | ---: | ---: | ---: | ---: |
| Net margin | -2.4% | 3.2% | 35 | 56 |
| Operating margin | 11.8% | 5.5% | 82 | 51 |
| Revenue growth | 6.2% | 11.8% | 32 | 57 |
| FCF margin | 5.9% | 5.4% | 51 | 48 |
| ROE | -4.5% | 7.9% | 37 | 53 |
| ROA | -1.0% | 2.8% | 39 | 58 |
| Liabilities / equity | 3.74 | 1.13 | 81 | 54 |
| Current ratio | 1.87 | 1.63 | 61 | 58 |

Percentile = share of the N covered peers reporting that ratio whose value is lower (ties counted half); computed among grepcent-covered companies in SIC major-group 80 SIC Major Group 80, not the whole market. A higher percentile means a higher value of the ratio, not a better company. Ratios with fewer than 8 reporting peers are omitted. Latest reported values per company; fiscal periods may differ. Descriptive arithmetic - not a score, rating, or ranking.

## Selected Fundamentals
| Metric | Value | Unit | FY | Filed |
| --- | ---: | --- | ---: | --- |
| Revenue | 3308700000 | USD | 2025 | 2026-03-02 |
| Net income | -77900000 | USD | 2025 | 2026-03-02 |
| Assets | 8119700000 | USD | 2025 | 2026-03-02 |

## Financials

Annual standardized facts from SEC companyfacts as of latest extracted filing date 2026-03-02. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0001638833.json. Derived margins, ratios, and free cash flow are computed from the extracted annual SEC facts.

| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue |  | 1,145,438,000 | 460,346,000 | 1,771,500,000 | 1,831,400,000 | 1,860,100,000 | 2,225,100,000 | 2,539,300,000 | 2,743,300,000 | 3,114,300,000 | 3,308,700,000 |
| Net income | 1,429,000 | 9,453,000 |  | -205,700,000 | -74,800,000 | -116,100,000 | -70,900,000 | -54,600,000 | -11,900,000 | -168,100,000 | -77,900,000 |
| Operating income | 144,754,000 | 196,482,000 |  | 77,800,000 | 235,900,000 | 183,000,000 | 302,200,000 | 345,200,000 | 328,000,000 | 348,800,000 | 389,500,000 |
| Diluted EPS | 0.04 | 0.20 |  | -4.96 | -2.29 | -3.19 | -1.12 | -0.59 | -0.09 | -1.33 | -0.61 |
| Operating cash flow | 84,481,000 | 125,239,000 |  | 144,600,000 | 129,500,000 | 246,900,000 | 87,100,000 | 158,800,000 | 293,800,000 | 300,100,000 | 274,300,000 |
| Capital expenditures | 33,439,000 | 39,109,000 |  | 39,800,000 | 73,600,000 | 42,900,000 | 57,600,000 | 80,600,000 | 88,800,000 | 90,400,000 | 78,700,000 |
| Assets |  | 2,304,958,000 | 4,622,773,000 | 4,676,300,000 | 5,018,900,000 | 5,413,200,000 | 6,117,600,000 | 6,682,100,000 | 6,876,700,000 | 7,890,000,000 | 8,119,700,000 |
| Stockholders' equity |  | 9,677,000 | 654,731,000 | 404,600,000 | 296,800,000 | 115,600,000 | 1,089,000,000 | 1,998,200,000 | 1,987,200,000 | 1,789,700,000 | 1,712,900,000 |
| Cash and cash equivalents |  | 69,699,000 | 174,914,000 | 184,300,000 | 92,700,000 | 317,900,000 | 389,900,000 | 282,900,000 | 195,900,000 | 269,500,000 | 239,900,000 |
| Free cash flow | 51,042,000 | 86,130,000 |  | 104,800,000 | 55,900,000 | 204,000,000 | 29,500,000 | 78,200,000 | 205,000,000 | 209,700,000 | 195,600,000 |

### Ratios

ROE and ROA use period-end equity/assets. Liabilities / equity uses total liabilities divided by stockholders' equity. Current ratio uses current assets divided by current liabilities when both are reported.

| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Net margin |  | 0.83% |  | -11.61% | -4.08% | -6.24% | -3.19% | -2.15% | -0.43% | -5.40% | -2.35% |
| Operating margin |  | 17.15% |  | 4.39% | 12.88% | 9.84% | 13.58% | 13.59% | 11.96% | 11.20% | 11.77% |
| Return on equity |  | 97.69% |  | -50.84% | -25.20% | -100.43% | -6.51% | -2.73% | -0.60% | -9.39% | -4.55% |
| Return on assets |  | 0.41% |  | -4.40% | -1.49% | -2.14% | -1.16% | -0.82% | -0.17% | -2.13% | -0.96% |
| Liabilities / equity |  |  | 6.06 | 10.56 | 15.91 | 45.83 | 4.62 | 2.34 | 2.46 | 3.41 | 3.74 |
| Current ratio |  | 1.94 | 1.86 | 1.68 | 1.32 | 1.44 | 1.76 | 1.87 | 1.71 | 1.79 | 1.87 |

## As-reported value updates

No tracked differences above grepcent's stated thresholds and capped precision rule were found between the earliest XBRL-filed value and the value currently on file for the standardized annual metrics grepcent tracks.


## Quarterly

Quarterly standardized facts from SEC companyfacts as of latest extracted filing date 2026-08-10. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0001638833.json.

Flow metrics use discrete quarter-length periods from 10-Q/10-Q/A filings. Q4 revenue and net income are derived only when annual FY and nine-month YTD facts exist for the same fiscal year; derived Q4 values are labeled. EPS Q4 is not derived.

| Quarter | End date | Revenue | Net income | Diluted EPS | Method |
| --- | --- | ---: | ---: | ---: | --- |
| 2022-Q3 | 2022-09-30 |  |  | -0.28 | reported discrete quarter |
| 2023-Q1 | 2023-03-31 |  |  | -0.20 | reported discrete quarter |
| 2023-Q2 | 2023-06-30 |  |  | 0.15 | reported discrete quarter |
| 2023-Q3 | 2023-09-30 | 674,100,000 | -4,900,000 | -0.04 | reported discrete quarter |
| 2023-Q4 | 2023-12-31 | 735,400,000 | -1,000,000 |  | derived Q4 = FY annual - nine-month YTD |
| 2024-Q1 | 2024-03-31 | 717,400,000 | -12,400,000 | -0.10 | reported discrete quarter |
| 2024-Q2 | 2024-06-30 | 762,100,000 | -15,500,000 | -0.12 | reported discrete quarter |
| 2024-Q3 | 2024-09-30 | 770,400,000 | -31,700,000 | -0.25 | reported discrete quarter |
| 2024-Q4 | 2024-12-31 | 864,400,000 | -108,500,000 |  | derived Q4 = FY annual - nine-month YTD |
| 2025-Q1 | 2025-03-31 | 776,000,000 | -37,700,000 | -0.30 | reported discrete quarter |
| 2025-Q2 | 2025-06-30 | 826,200,000 | -2,500,000 | -0.02 | reported discrete quarter |
| 2025-Q3 | 2025-09-30 | 821,500,000 | -22,700,000 | -0.18 | reported discrete quarter |
| 2025-Q4 | 2025-12-31 | 885,000,000 | -15,000,000 |  | derived Q4 = FY annual - nine-month YTD |
| 2026-Q1 | 2026-03-31 | 810,900,000 | -35,900,000 | -0.28 | reported discrete quarter |
| 2026-Q2 | 2026-06-30 | 848,900,000 | -15,000,000 | -0.12 | reported discrete quarter |

## Filed narrative (10-K & 10-Q)

## Business

Verbatim Item 1 Business section from SGRY's latest 10-K: [/company/SGRY/business/](/company/SGRY/business/).

## Risk Factors

Verbatim Item 1A Risk Factors from SGRY's latest 10-K: [/company/SGRY/risk-factors/](/company/SGRY/risk-factors/).

## Latest quarter (10-Q)

Latest 10-Q source: https://www.sec.gov/Archives/edgar/data/1638833/000163883326000077/sgry-20260630.htm

Extracted structurally from real Item 2 body heading to real Item 3/4 boundary.
Confidence: high
Filing date: 2026-08-10
Report date: 2026-06-30

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the condensed consolidated financial statements and related notes included elsewhere in this report and our 2025 Annual Report on Form 10-K. Unless the context otherwise indicates, the terms "Surgery Partners," "we," "us," "our" or the "Company," as used herein, refer to Surgery Partners, Inc. and its subsidiaries, and the term "affiliates" means direct and indirect subsidiaries of Surgery Partners, Inc. and partnerships and joint ventures in which such subsidiaries are partners. The terms "facilities" or "hospitals" refer to entities owned and operated by affiliates of Surgery Partners, Inc. and the term "employees" refers to employees of affiliates of Surgery Partners, Inc.

Cautionary Note Regarding Forward-Looking Statements

This report contains forward-looking statements, which are based on our current expectations, estimates and assumptions about future events. All statements other than statements of current or historical fact contained in this report are forward-looking statements. These statements include, but are not limited to, statements regarding our future financial position, business strategy, budgets, effective tax rate, projected costs and plans and objectives of management for future operations. The words "projections," "believe," "continue," "drive," "estimate," "expect," "intend," "may," "plan," "will," "could," "would" and similar expressions are generally intended to identify forward-looking statements.

By their nature, forward-looking statements involve risks, uncertainties and other factors that may cause actual results to differ from the expectations expressed in the statements. Many of these factors are beyond our ability to control or predict. These factors include, without limitation, the risk that the potential sale transaction of our ownership interests in Mountain View Hospital and Idaho Falls Community Hospital to Intermountain Health may not be completed in a timely manner or at all, including the risk that required physician, regulatory and other approvals and consents are not obtained, are delayed, or are obtained subject to conditions that are not anticipated; the failure to satisfy other closing conditions to the transaction; the possibility that the anticipated benefits of the sale to us are not realized as expected, the potential adverse effect of the announcement or pendency of the transaction on the market price of, or trading in, our securities and on our business relationships, operating results, and business generally, including the ability to retain key personnel; risks related to diverting management's attention from our ongoing business operations; the amount of costs, fees, expenses, and charges related to the sale transaction; potential litigation relating to the transaction that could be instituted against us or our affiliates, officers, or directors, and the effects of any outcomes related thereto; reductions in payments from government health care programs and private insurance payors, such as health maintenance organizations, preferred provider organizations, and other managed care organizations and employers; our ability to contract with private insurance payors; changes in our payor mix or surgical case mix; failure to maintain or develop relationships with physicians on beneficial or favorable terms, or at all; the impact of payor controls designed to reduce the number of surgical procedures; our efforts to integrate operations of acquired businesses and surgical facilities, attract new physician partners, or acquire additional surgical facilities; supply chain issues, including shortages or quality control issues with surgery-related products, equipment and medical supplies; competition for physicians, nurses, strategic relationships, acquisitions and managed care contracts; our ability to attract and retain qualified health care professionals; our ability to enforce non-compete restrictions against our physicians; our ability to manage material liabilities whether known or unknown incurred as a result of acquiring surgical facilities; the impact of current and future legislation and other health care public policy changes, and the effect of that legislation and other regulatory actions on our business; our ability to comply with current health care laws and regulations; the outcome of legal and regulatory proceedings that have been or may be brought against us; the impact of cybersecurity attacks or intrusions; changes in the regulatory, economic and other conditions of the states where our surgical facilities are located; our indebtedness; the social and economic impact of a pandemic, epidemic or outbreak of a contagious disease on our business; and the risks and uncertainties set forth under the heading "Risk Factors" in our 2025 Annual Report on Form 10-K and discussed from time to time in our reports filed with the Securities and Exchange Commission.

Considering these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this report may not occur, and actual results could differ materially from those anticipated or implied in the forward-looking statements. When you consider these forward-looking statements, you should keep in mind these risk factors and other cautionary statements in this report.

These forward-looking statements speak only as of the date made. Other than as required by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events or otherwise.

Executive Overview

As of June 30, 2026, we owned or operated, primarily in partnership with physicians, a portfolio of 178 surgical facilities comprised of 159 ASCs and 19 surgical hospitals across 30 states. We owned a majority interest in 87 of the surgical facilities and consolidated 120 of these facilities for financial reporting purposes.

Total revenues for the second quarter of 2026 increased 2.7% to $848.9 million from $826.2 million in the second quarter of 2025. The increase in revenues was attributable to same-facility revenue growth in 2026. Days adjusted same-facility revenues for the second quarter of 2026 increased 5.0% from the second quarter of 2025, with a 4.8% increase in revenue per case and a 0.3% increase in same-facility cases. Additionally, for the second quarter of 2026, net loss attributable to Surgery Partners, Inc. was $15.0 million compared to $2.5 million for the second quarter of 2025. For the second quarter of 2026, Adjusted EBITDA decreased 2.9% to $125.2 million compared to $129.0 million for the same period in 2025. A reconciliation of non-GAAP financial measures appears below under the heading "Certain Non-GAAP Measures."

We continue to focus on improving our same-facility performance, selectively acquiring established facilities, developing new facilities and pursuing other portfolio management initiatives.

18

Table of Contents

We had cash and cash equivalents of $216.7 million and $617.8 million of borrowing capacity under the Revolver as of June 30, 2026.

Revenues

Our revenues consist of patient service revenues and other service revenues. Patient service revenues consist of revenue from our Surgical Facilities reportable segment. Specifically, patient service revenues include fees for surgical or diagnostic procedures performed at surgical facilities that we consolidate for financial reporting purposes, as well as for patient visits to our physician practices, anesthesia services, pharmacy services and diagnostic screens ordered by our physicians. Other service revenues include management and administrative service fees derived from our non-consolidated facilities that we account for under the equity method, management of surgical facilities and physician practices in which we do not own an interest, management services we provide to physician practices for which we are not required to provide capital or additional assets and other non-patient services.

The following table summarizes revenues by service type as a percentage of total revenues:

[[GREPCENT_TABLE]]
[["","","Three Months Ended June 30,","","Six Months Ended June 30,"],["","","2026","","2025","","2026","","2025"],["Patient service revenues:"],["Patient service revenues","","97.3","%","","97.3","%","","97.5","%","","97.5","%"],["Other service revenues","","2.7","%","","2.7","%","","2.5","%","","2.5","%"],["Total revenues","","100.0","%","","100.0","%","","100.0","%","","100.0","%"]]
[[/GREPCENT_TABLE]]

Payor Mix

The following table sets forth by type of payor the percentage of our patient service revenues generated at the surgical facilities that we consolidate for financial reporting purposes:

[[GREPCENT_TABLE]]
[["","","Three Months Ended June 30,","","Six Months Ended June 30,"],["","","2026","","2025","","2026","","2025"],["Private insurance payors","","48.6","%","","52.1","%","","49.5","%","","52.0","%"],["Government payors","","46.1","%","","42.9","%","","45.6","%","","43.1","%"],["Self-pay payors","","2.8","%","","2.7","%","","2.6","%","","2.7","%"],["Other payors (1)","","2.5","%","","2.3","%","","2.3","%","","2.2","%"],["Total","","100.0","%","","100.0","%","","100.0","%","","100.0","%"]]
[[/GREPCENT_TABLE]]

(1)Comprised of automobile liability, letters of protection and other payor types.

Surgical Case Mix

We primarily operate multi-specialty surgical facilities where physicians perform a variety of procedures in various specialties. We believe this diversification helps to protect us from adverse pricing and utilization trends in any individual procedure type and results in greater consistency in our case volume.

The following table sets forth the percentage of cases in each specialty performed at the surgical facilities that we consolidate for financial reporting purposes for the periods indicated:

[[GREPCENT_TABLE]]
[["","","Three Months Ended June 30,","","Six Months Ended June 30,"],["","","2026","","2025","","2026","","2025"],["Orthopedics and pain management","","40.1","%","","39.8","%","","40.6","%","","40.2","%"],["Ophthalmology","","20.8","%","","22.2","%","","20.7","%","","22.1","%"],["Gastrointestinal","","23.7","%","","24.8","%","","23.7","%","","24.6","%"],["General surgery","","1.9","%","","1.8","%","","1.9","%","","2.0","%"],["Other","","13.5","%","","11.4","%","","13.1","%","","11.1","%"],["Total","","100.0","%","","100.0","%","","100.0","%","","100.0","%"]]
[[/GREPCENT_TABLE]]

19

Table of Contents

Critical Accounting Policies

A summary of significant accounting policies is disclosed in our 2025 Annual Report on Form 10-K under the caption “Critical Accounting Policies” in the Management’s Discussion and Analysis of Financial Condition and Results of Operations section. There have been no material changes in the nature of our critical accounting policies or the application of those policies since December 31, 2025.

Results of Operations

Comparison of Operating Results for the Three Months Ended June 30, 2026 to the Three Months Ended June 30, 2025

The following tables summarize certain results from the condensed consolidated statements of operations for the periods indicated (in millions):

[Excerpt truncated for page length; source filing is linked above.]

## Latest 10-K MD&A (excerpt)

Latest 10-K Item 7 source: https://www.sec.gov/Archives/edgar/data/1638833/000163883326000008/sgry-20251231.htm
Complete FY 2025 MD&A: /company/SGRY/mda/fy2025/

Extracted structurally from real Item 7 body heading to real Item 7A/8 boundary.
Confidence: high
Filing date: 2026-03-02
Report date: 2025-12-31

Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our audited consolidated financial statements and related notes included elsewhere in this Annual Report. This discussion contains forward-looking statements that involve risks and uncertainties. For additional information regarding certain of the risks and uncertainties that affect our business and the industry in which we operate, please see Item 1A. "Risk Factors" and Item 9A. "Controls and Procedures" found elsewhere in this Annual Report. Unless the context otherwise indicates, the terms "Surgery Partners," "we," "us," "our" or the "Company," as used herein, refer to Surgery Partners, Inc. and its subsidiaries. Unless the context implies otherwise, the term "affiliates" means direct and indirect subsidiaries of Surgery Partners, Inc. and partnerships and joint ventures in which such subsidiaries are partners. The terms "facilities" or "hospitals" refer to entities owned and operated by affiliates of Surgery Partners, Inc. and the term "employees" refers to employees of affiliates of Surgery Partners, Inc.

Executive Overview

As of December 31, 2025, we owned or operated, primarily in partnership with physicians, a portfolio of 176 surgical facilities comprised of 157 ASCs and 19 surgical hospitals across 30 states. We owned a majority interest in 90 of the surgical facilities and consolidated 121 of these facilities for financial reporting purposes.

Total revenues for 2025 increased 6.2% to $3.3 billion from $3.1 billion in 2024. The increase in revenues was attributable to same-facility revenue growth and the net impact from acquisitions and divestitures completed in 2025. Days adjusted same-facility revenues for 2025 increased 4.9% from 2024, with a 1.4% increase in revenue per case and a 3.4% increase in same-facility cases. Additionally, for 2025, net loss attributable to Surgery Partners, Inc. was $77.9 million compared to $168.1 million for 2024. For 2025, Adjusted EBITDA increased 3.5% to $526.2 million compared to $508.2 million for 2024. The increase in Adjusted EBITDA was primarily attributable to revenue growth, continued cost management initiatives and acquisitions completed since the prior year. A reconciliation of non-GAAP financial measures appears below under the heading "Certain Non-GAAP Measures."

We continue to focus on improving our same-facility performance, selectively acquiring established facilities, developing new facilities and pursuing other portfolio management initiatives. During 2025, we acquired a controlling interest in twelve surgical facilities and several physician practices and other ancillary businesses for aggregate cash consideration of $162.1 million, net of cash acquired.

We had cash and cash equivalents of $239.9 million and $692.8 million of borrowing capacity under the Revolver as of December 31, 2025.

Recent Legislation

On July 4, 2025, Congress passed the One Big Beautiful Bill Act (the “OBBBA”), which introduced significant changes to federally funded healthcare programs, including Medicaid, Medicare, and the Affordable Care Act. While such changes are projected to reduce overall healthcare spending and increase regulatory burdens in certain jurisdictions in which the Company operates, they are not expected to materially impact the Company's financial statements.

The OBBBA also makes permanent key elements of the Tax Cuts and Jobs Act including, among others, 100% bonus depreciation and the business interest expense limitations. The Company’s tax provision for the year ended December 31, 2025, incorporates the effects of these tax law changes.

Revenues

Our revenues consist of patient service revenues and other service revenues. Patient service revenues consist of revenue from our Surgical Facilities reportable segment. Specifically, patient service revenues include fees for surgical or diagnostic procedures performed at surgical facilities that we consolidate for financial reporting purposes, as well as for patient visits to our physician practices, anesthesia services, pharmacy services and diagnostic screens ordered by our physicians. Other service revenues include management and administrative service fees derived from our non-consolidated facilities that we account for under the equity method, management of

30

Table of Contents

surgical facilities and physician practices in which we do not own an interest, management services we provide to physician practices for which we are not required to provide capital or additional assets and other non-patient services.

The following table summarizes revenues by service type as a percentage of total revenues:

[[GREPCENT_TABLE]]
[["","","","","Year Ended December 31,"],["","","","","","","2025","","2024","","2023"],["Patient service revenues:"],["Patient service revenues","","","","","","97.5","%","","98.1","%","","98.4","%"],["Other service revenues","","","","","","2.5","%","","1.9","%","","1.6","%"],["Total revenues","","","","","","100.0","%","","100.0","%","","100.0","%"]]
[[/GREPCENT_TABLE]]

Payor Mix

The following table sets forth by type of payor the percentage of our patient service revenues generated at the surgical facilities that we consolidate for financial reporting purposes:

[[GREPCENT_TABLE]]
[["","","","","Year Ended December 31,"],["","","","","","","2025","","2024","","2023"],["Private insurance payors","","","","","","52.3","%","","53.5","%","","52.5","%"],["Government payors","","","","","","42.8","%","","41.1","%","","41.8","%"],["Self-pay payors","","","","","","2.7","%","","2.7","%","","2.5","%"],["Other payors (1)","","","","","","2.2","%","","2.7","%","","3.2","%"],["Total","","","","","","100.0","%","","100.0","%","","100.0","%"]]
[[/GREPCENT_TABLE]]

(1)Comprised of automobile liability, letters of protection and other payor types.

Surgical Case Mix

We primarily operate multi-specialty surgical facilities where physicians perform a variety of procedures in various specialties. We believe this diversification helps to protect us from adverse pricing and utilization trends in any individual procedure type and results in greater consistency in our case volume.

The following table sets forth the percentage of cases in each specialty performed at the surgical facilities that we consolidate for financial reporting purposes for the periods indicated:

[[GREPCENT_TABLE]]
[["","","","","Year Ended December 31,"],["","","","","","","2025","","2024","","2023"],["Orthopedics and pain management","","","","","","40.7","%","","40.2","%","","36.1","%"],["Ophthalmology","","","","","","21.7","%","","23.3","%","","24.4","%"],["Gastrointestinal","","","","","","24.4","%","","22.6","%","","23.7","%"],["General surgery","","","","","","1.9","%","","2.3","%","","2.6","%"],["Other","","","","","","11.3","%","","11.6","%","","13.2","%"],["Total","","","","","","100.0","%","","100.0","%","","100.0","%"]]
[[/GREPCENT_TABLE]]

31

Table of Contents

Segment Information

Our business is comprised of one reportable segment, Surgical Facilities. For more information about the components of the reportable segment, please see Part I, Item 1. "Business-Operations" included elsewhere in this Annual Report. The "All other" line item below primarily consists of amounts attributable to the Company's corporate general and administrative functions.

The following tables present financial information for the reportable segment (in millions):

[[GREPCENT_TABLE]]
[["","","Year Ended December 31,"],["","","2025","","2024","","2023"],["Revenues:"],["Surgical Facilities","","$","3,308.7","","","$","3,114.3","","","$","2,743.3"],["Total revenues","","$","3,308.7","","","$","3,114.3","","","$","2,743.3"],["Adjusted EBITDA:"],["Surgical Facilities","","$","626.7","","","$","610.0","","","$","534.3"],["All Other","","(100.5)","","","(101.8)","","","(96.2)"],["Total Adjusted EBITDA (1)","","$","526.2","","","$","508.2","","","$","438.1"],["Depreciation and amortization:"],["Surgical Facilities","","$","164.8","","","$","138.9","","","$","110.8"],["All other","","11.2","","","13.7","","","7.3"],["Total depreciation and amortization expense","","$","176.0","","","$","152.6","","","$","118.1"],["Supplemental Information:"],["Cash purchases of property and equipment, net:"],["Surgical Facilities","","$","77.9","","","$","86.6","","","$","88.7"],["All Other","","0.8","","","3.8","","","0.1"],["Total cash purchases of property and equipment, net","","$","78.7","","","$","90.4","","","$","88.8"]]
[[/GREPCENT_TABLE]]

(1)For a reconciliation of Adjusted EBITDA to income before income taxes as reflected in the audited consolidated statements of operations see "Certain Non-GAAP Measures" below.

[[GREPCENT_TABLE]]
[["","","December 31,"],["","","2025","","2024"],["Assets:"],["Surgical Facilities","","$","7,643.9","","","$","7,466.3"],["All Other","","475.8","","","423.7"],["Total assets","","$","8,119.7","","","$","7,890.0"]]
[[/GREPCENT_TABLE]]

Critical Accounting Policies

In preparing our consolidated financial statements in conformity with U.S. Generally Accepted Accounting Principles ("GAAP"), we must use estimates and assumptions that affect the reported amounts of assets and liabilities and related disclosures and the reported amounts of revenue and expenses. In general, our estimates are based on historical experience and various other assumptions we believe are reasonable under the circumstances. We evaluate our estimates on an ongoing basis and make changes to the estimates and related disclosures as experience develops or new information becomes known. Actual results could differ from those estimates.

We consider our critical accounting policies to be those that involve significant judgments and uncertainties, and may potentially result in materially different results under different assumptions and conditions.

Revenue Recognition

Our patient service revenues are derived primarily from surgical procedures performed at our surgical facilities, patient visits to physician practices, anesthesia services provided to patients, pharmacy services and diagnostic screens ordered by our physicians. The fees for such services are billed either to the patient or a third-party payor, including Medicare and Medicaid. We recognize patient service

32

Table of Contents

revenues, net of contractual adjustments and implicit price concessions. Contractual adjustments and implicit price concessions are estimated based on contractual agreements, discount policies and historical experience of cash collections and historical write-offs. The estimated contractual adjustments are recognized at the time of services being performed, with ASCs typically based on contractual agreements and surgical hospitals typically based on historical experience of cash collections and write-offs. Changes in estimated contractual adjustments are recorded in the period of change, with final adjustments, if any, typically at the time of payment.

Other service revenues consist of management and administrative service fees derived from non-consolidated surgical facilities that we account for under the equity method, management of surgical facilities in which we do not own an interest and management services we provide to physician networks for which we are not required to provide capital or additional assets. The fees we derive from these management arrangements are generally based on a predetermined percentage of the revenues of each surgical facility and physician network. We recognize other service revenues in the period in which services are rendered and billed.

There were no material impacts on our financial condition or results of operations due to changes in assumptions or conditions related to revenue recognition during the years ended December 31, 2025, 2024 and 2023.

Accounts Receivable

[Excerpt truncated for page length; the complete text is on the linked full-MD&A page.]

Read the full FY 2025 MD&A: /company/SGRY/mda/fy2025/
All MD&A years: /company/SGRY/mda/


## MD&A history

Prior-year 10-K MD&A spans are extracted from SEC filings with the same bounded parser used for the latest filing. Each year's full verbatim text is on its own sub-page.

- [FY 2024 MD&A](/company/SGRY/mda/fy2024/): filed 2025-03-07; accession 0001638833-25-000053 (https://www.sec.gov/Archives/edgar/data/1638833/000163883325000053/sgry-20241231.htm)
- [FY 2023 MD&A](/company/SGRY/mda/fy2023/): filed 2024-02-26; accession 0001638833-24-000029 (https://www.sec.gov/Archives/edgar/data/1638833/000163883324000029/sgry-20231231.htm)
- [FY 2022 MD&A](/company/SGRY/mda/fy2022/): filed 2023-03-01; accession 0001638833-23-000021 (https://www.sec.gov/Archives/edgar/data/1638833/000163883323000021/sgry-20221231.htm)
- [FY 2021 MD&A](/company/SGRY/mda/fy2021/): filed 2022-03-01; accession 0001638833-22-000019 (https://www.sec.gov/Archives/edgar/data/1638833/000163883322000019/sgry-20211231.htm)




## Macro cross-references

Indicators mapped to this company's SIC classification (industry 8062 Services-General Medical & Surgical Hospitals, NEC) by grepcent's deterministic macro-sector crosswalk. A navigational mapping, not a statistical or causal claim.

- [PCE](/indicator/PCE/): Personal Consumption Expenditures
- [GDPC1](/indicator/GDPC1/): Real Gross Domestic Product
- [PAYEMS](/indicator/PAYEMS/): All Employees, Total Nonfarm
- [CES0500000003](/indicator/CES0500000003/): Average Hourly Earnings of All Employees, Total Private
- [UNRATE](/indicator/UNRATE/): Unemployment Rate
- [DSPIC96](/indicator/DSPIC96/): Real Disposable Personal Income

Macro-to-micro threads including this sector: [US labor market](/thread/us-labor-market/), [Growth & output](/thread/growth-output/), [Government finances](/thread/government-finances/), [Sector employment](/thread/sector-employment/).

All macro indicators: /indicators/


## For LLMs & downloads

Markdown twin: /company/SGRY.md · JSON record: /company/SGRY.json · verified financials: /company/SGRY/financials.json / /company/SGRY/financials.csv · machine TOC for the whole site: /llms.txt